Tyra Biosciences Inc
TYRA10.636USD
+0.266+2.57%
交易中 （美东）报价延迟15分钟
564.69M总市值
亏损市盈率 TTM
关于 Tyra Biosciences Inc 公司
Tyra Biosciences, Inc. 是一家临床阶段的生物技术公司。该公司专注于开发针对成纤维细胞生长因子受体 (FGFR) 生物学领域的巨大机遇的精准药物。其内部精准医疗平台 SNAP 通过迭代分子 SNAPshot 实现快速而精准的药物设计，有助于预测导致对现有疗法产生获得性耐药性的基因变异。该公司最初的重点是应用其加速小分子药物发现引擎来开发针对肿瘤和基因定义疾病的疗法。其主要候选产品 TYRA-300 是一种在研的口服 FGFR3 选择性抑制剂，正在国际、多中心、开放标签 1 期临床研究 SURF301 中进行评估。其第二个肿瘤候选产品 TYRA-200 是一种在研的口服 FGFR1/2/3 抑制剂，具有抗激活 FGFR2 基因变异以及临床上重要的分子制动和守门人耐药突变的功效。
公司简介
公司代码TYRA
公司名称Tyra Biosciences Inc
上市日期Sep 15, 2021
CEODr. Todd James Harris, Ph.D.
员工数量60
证券类型Ordinary Share
年结日Sep 15
公司地址2656 State Street
城市CARLSBAD
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92008
电话16197284760
网址https://tyra.bio/
公司代码TYRA
上市日期Sep 15, 2021
CEODr. Todd James Harris, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rehan Verjee
Mr. Rehan Verjee
Independent Director
Independent Director
--
--
Dr. S. Michael Rothenberg, M.D., Ph.D.
Dr. S. Michael Rothenberg, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas (Doug) Warner, M.D.
Dr. Douglas (Doug) Warner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy Conrad
Ms. Amy Conrad
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Todd James Harris, Ph.D.
Dr. Todd James Harris, Ph.D.
President, Chief Executive Officer, Treasurer, Director
President, Chief Executive Officer, Treasurer, Director
1.36M
+0.09%
Mr. Daniel Bensen
Mr. Daniel Bensen
Chief Operating Officer
Chief Operating Officer
427.98K
--
Dr. Gilla Kaplan, Ph.D.
Dr. Gilla Kaplan, Ph.D.
Independent Director
Independent Director
28.23K
-68.50%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Chairman of the Board
Independent Chairman of the Board
24.43K
--
Dr. Susan M. Moran, M.D.
Dr. Susan M. Moran, M.D.
Independent Director
Independent Director
--
--
Mr. Alan Fuhrman, CPA
Mr. Alan Fuhrman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 6月11日 周三
更新时间: 6月11日 周三
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
22.94%
Alta Partners
7.67%
Nextech Invest, Ltd.
7.63%
BVF Partners L.P.
7.42%
Canaan Partners
6.79%
Other
47.56%
持股股东
持股股东
占比
RA Capital Management, LP
22.94%
Alta Partners
7.67%
Nextech Invest, Ltd.
7.63%
BVF Partners L.P.
7.42%
Canaan Partners
6.79%
Other
47.56%
股东类型
持股股东
占比
Venture Capital
39.16%
Investment Advisor
23.43%
Hedge Fund
23.32%
Investment Advisor/Hedge Fund
15.94%
Individual Investor
3.49%
Private Equity
3.30%
Research Firm
0.89%
Pension Fund
0.27%
Bank and Trust
0.12%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
236
58.55M
110.09%
+1.18M
2025Q1
239
56.06M
105.46%
-647.87K
2024Q4
219
50.96M
100.70%
-3.70M
2024Q3
195
53.66M
101.74%
-3.04M
2024Q2
179
53.85M
102.74%
-1.82M
2024Q1
167
53.85M
102.76%
+5.34M
2023Q4
151
42.86M
99.62%
-3.01M
2023Q3
152
44.80M
104.35%
-3.44M
2023Q2
147
44.53M
104.65%
-3.27M
2023Q1
133
44.06M
103.88%
+915.22K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
12.20M
22.94%
+1.56M
+14.68%
Jun 16, 2025
Alta Partners
4.08M
7.67%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
4.06M
7.63%
--
--
Mar 31, 2025
BVF Partners L.P.
3.94M
7.42%
--
--
Mar 31, 2025
Canaan Partners
4.14M
7.79%
-35.27K
-0.84%
Mar 31, 2025
TCG Crossover Management, LLC
2.90M
5.45%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.88M
5.42%
+1.89M
+190.89%
Mar 31, 2025
Commodore Capital LP
2.75M
5.17%
+1.80M
+189.47%
May 07, 2025
Janus Henderson Investors
2.69M
5.06%
+946.92K
+54.22%
Mar 31, 2025
Kynam Capital Management LP
2.41M
4.52%
+1.88M
+353.57%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
ALPS Medical Breakthroughs ETF
0.34%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
JPMorgan Fundamental Data Science Small Core ETF
0.05%
iShares Micro-Cap ETF
0.05%
iShares Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.83%
ALPS Medical Breakthroughs ETF
占比0.34%
ProShares Ultra Nasdaq Biotechnology
占比0.06%
Invesco Nasdaq Biotechnology ETF
占比0.06%
JPMorgan Fundamental Data Science Small Core ETF
占比0.05%
iShares Micro-Cap ETF
占比0.05%
iShares Biotechnology ETF
占比0.03%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
